Viking Therapeutics (VKTX) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Citi Starts Viking Therapeutic (VKTX) at Neutral
February 7, 2025 6:52 AM ESTCiti analyst David Lebowitz initiates coverage on Viking Therapeutic (NASDAQ: VKTX) with a Neutral rating and a price target of $38.00.
The analyst comments "The relatively recent emergence of GLP-1s for the treatment of obesity has rapidly established a megamarket opportunity... More
Viking Therapeutic (VKTX) PT Lowered to $95 at Truist Securities
February 6, 2025 12:07 PM ESTTruist Securities analyst Joon Lee lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $95.00 (from $120.00) while maintaining a Buy rating.
The analyst comments "4Q24 update narrowed timeline for the start of 2x Ph3 studies of SQVK2735 in obesity. Toplines from Ph3... More
